Phase 2b, randomized, double-blind, placebo-controlled study to evaluate antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of orally administered study drug regimens in hospitalized adult patients with respiratory syncytia virus infection.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: JANSSEN-CILAG INTERNATIONAL NV
- Phase: II
- Execution start: 03/11/2016
- End of execution: 31/12/2018
- PI: JUAN PASQUAU LIAÑO